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Abstract
Background: Asthma is a chronic lung disease in which recurrent asthma symptoms create a substantial
burden to individuals and their families. At the same time the economic burden associated with asthma is
considerable.
Methods: The cost-effectiveness study was part of a single centre prospective randomised controlled trial
comparing a nurse-led telemonitoring programme to usual care in a population of asthmatic outpatients.
The study included 109 asthmatic outpatients (56 children; 53 adults). The duration of follow-up was 12
months, and measurements were performed at baseline, 4, 8, and 12 months. Patients were asked to
transfer their monitor data at least twice daily and by judging the received data and following a stepwise
intervention protocol a nurse was able to act as the main caregiver in the intervention group. In both
groups the EQ-5D and the SF-6D were used to obtain estimates of health state utilities. One year health
care costs, patient and family costs, and productivity losses were calculated. The mean incremental costs
were weighted against the mean incremental effect in terms of QALY.
Results:  The study population generally represented mild to moderate asthmatics. No significant
differences were found between the groups with regard to the generic quality of life. Overall, the mean
health care costs per patient were higher in the intervention group than in the control group. The
intervention costs mainly caused the cost difference between the groups. The intervention costs the
society € 31,035/QALY gained with regard to adults and with regard to children € 59,071/QALY gained.
Conclusion:  If the outcome is measured by generic quality of life the nurse-led telemonitoring
programme is of limited cost-effectiveness in the study population. From the societal perspective the
probability of the programme being cost-effective compared to regular care was 85% at a ceiling ratio of
€ 80,000/QALY gained among the adults and 68% among the children. A decrease in the price of the
asthma monitor will substantial increase the probability of the programme to be cost-effective.
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Background
Asthma is a chronic lung disease from which worldwide
300 million people suffer. Among children it is even the
most common chronic disease. Recurrent asthma symp-
toms create a substantial burden to individuals and their
families and lead to restriction of an individual's activi-
ties. Asthma can be successfully controlled with proper
care, which enables patients to enjoy good quality of life
[1]. In a continuous cycle therapy should be adjusted by
assessment, treatment, and monitoring, depending on the
patient's level of control [2]. If asthma is not in control it
can lead to increase in medical consumption and to
school and work absenteeism. Consequently the eco-
nomic burden associated with asthma is considerable [1].
In the year 2000 the total costs for an asthma patient were
on average € 312 in the Netherlands. Medication costs
were the largest cost component in the direct costs (53%).
Furthermore, the medication costs were estimated to trip-
licate by the year 2025 [3]. A study performed in 2003 in
the USA has concluded that caring for a severe asthmatic
costs $12,813 a year (approximately € 10,000) [4]. The
largest components in the direct costs were medication
(53%) and hospital admissions (15%). Since financial
resources are scarce and technology is improving eco-
nomic evaluations are helpful in making decisions among
different health care interventions. This is particularly use-
ful to decide if a new health care technology should be
implemented. Economic evaluations present a compara-
tive analysis of alternative courses of actions in terms of
both their costs and consequences. The incremental cost
effectiveness ratio is defined as the difference in costs
between two technologies divided by the difference in
their benefits. The lower the incremental cost effectiveness
ratio, the more cost effective a technology [5].
Telemonitoring is a recent development in healthcare and
offers new method to manage asthma. By the use of tele-
monitors, spirometry tests can continuously be moni-
tored by transferring monitor data from the patient's
home to a central database. This monitoring at a distance
is very useful in the management of asthma, since asthma
cannot be cured and the presence of asthma symptoms
can change every day. In a recent literature review it was
stated that long-term disease monitoring of patients at
home stimulates cost-effectiveness in health care [6].
Nurses increasingly play a part in telemonitoring and
nurse-led telemonitoring programmes in chronic diseases
are commonly considered cost-effective. By employing a
nurse (practitioner) as the main caregiver costs can be
decreased to a minimum, while the quality of care stays
intact [7]. However, only a few studies have calculated
costs or incremental costs-effectiveness ratios [8]. To our
knowledge no study has performed a cost-effectiveness
analysis of a nurse-led telemonitoring intervention in
asthmatic outpatients.
The objective of this study was to determine the cost-effec-
tiveness of a nurse-led telemonitoring programme in asth-
matic outpatients compared to regular care. The study
protocol was approved by the appropriate ethics commit-
tee and informed consent was obtained from each partic-
ipant.
Methods
Data source
The cost-effectiveness study was part of a single centre pro-
spective randomised controlled trial comparing a nurse-
led telemonitoring programme to usual care in a popula-
tion of asthmatic outpatients. Randomisation took place
on patient level after stratification by age (children aged 7
to 18 versus adults aged 18 years and older). The duration
of follow-up was 12 months, and measurements were per-
formed at baseline, 4, 8, and 12 months.
The study population consisted of asthmatic outpatients
from the Medical Respiratory Department and the Depart-
ment of Paediatrics at the University Hospital Maastricht
in the Netherlands. Patients aged 7 and older with an
asthma severity of stage I – III as described in the Gina
guidelines were potentially eligible. The patients had to be
competent to use an asthma monitor, and had to possess
a household phone connection. Exclusion criteria were
severe co-morbidity (such as cystic fibrosis or congenital
lung abnormalities), since these patients frequently
require outpatient visits. The inclusion and exclusion cri-
teria were verified by the use of patient records. The power
calculation for this study was based on improvement in
asthma-specific quality of life, with a minimal important
difference of 0.5 points on the 7-point overall scale in the
Asthma Quality of Life Questionnaire (AQLQ) or the Pae-
diatric Asthma Quality of Life Questionnaire (PAQLQ) [9-
11]. One-sided testing, a power of 80%, and a significance
level of 0.05 with a drop out percentage of 10% resulted
in a minimal inclusion of 51 patients in the intervention
group and 51 patients in the control group.
This study focuses on the cost-effectiveness analyses. The
process evaluation and the effects of the main outcome
parameters ((P)AQLQ) are described elsewhere [12].
Comparators
The control group received regular outpatient care. In case
of stable asthma these patients received three to six
monthly medical check ups by their lung specialist or pae-
diatrician. In case of exacerbations the patients received
additional care from their general practitioner and/or out-
patient care. The intervention group used an asthma mon-
itor at home, and had a hospital-based nurse practitioner
(also referred to as the asthma nurse) as the main car-
egiver. The monitor was a portable hand-held device with
a matching modem. Patients were able to review theirCost Effectiveness and Resource Allocation 2007, 5:10 http://www.resource-allocation.com/content/5/1/10
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spirometry test results on the monitor screen. Transfers of
the monitor data to the nurse practitioner's computer
were performed by the patients by connecting the modem
to the household phone. Patients were instructed to per-
form daily lung function tests (both in the morning and
in the evening) and more often if they were having symp-
toms. Patients were asked to transfer the monitor data to
the nurse practitioner every month and more frequently if
they were having asthma symptoms. Patients with less
serious symptoms were instructed to call the nurse practi-
tioner during their programme participation. The nurse
practitioner studied the data and classified the asthma fol-
lowing a stepwise intervention protocol. According to this
protocol the nurse practitioner was allowed to decrease
(after 3 months of stable asthma) or increase (if asthma
was unstable) asthma medication by one step.
In case of an exacerbation the nurse practitioner judged if
the exacerbation was only an incident or more structural.
If he concluded that this was structural the nurse practi-
tioner had to increase the treatment by one therapy step as
described in the protocol. If standard treatment of an
exacerbation was not successful the nurse practitioner
contacted the treating physician to decide whether or not
a steroid course was necessary. In addition, according to
the protocol every 3 months the medication could be
changed (1 step up or down) by the nurse practitioner. If
the PEF curve was within normal range and the symptoms
were minimal the nurse practitioner asked the patients to
decrease the treatment level by one step. A physician was
only consulted if necessary. Following this procedure, the
nurse practitioner could adjust or maintain the treatment
due to the continuously monitoring.
Effects
Two multi-attribute utility instruments were used to
obtain estimates of health state utilities: the EQ-5D and
the SF-6D. Both instruments were administered at base-
line, and at 4, 8, and 12 months follow-up.
The EQ-5D consists of a descriptive system and a visual
analogue scale [13]. The five questions in the EQ-5D clas-
sify persons into one of 243 health states. The commonly
used scoring function for the EQ-5D is based on a British
study (EQ-5D UK) with preferences derived by the time
trade-off-method (TTO), in a representative sample of the
UK population [14]. The possible range of utility scores is
from -0.59 to 1.00. In the subgroup of children the EQ-5D
child version as previously used by Stolk et al. [15] was
used. Children aged 12 years and older completed this
Table 1: Baseline characteristics of the patients by age and group
Characteristics Adults (18 years and older) Children (7 – 18 years)
Control N = 27 Intervention N = 26 Control N = 27 Intervention N = 29
mean (sd)
age 45.90 (15.9) 45.65 (11.3) 10.85 (2.3) 10.57 (2.1)
lung function values
- FVC % pred 102.5 (15.3) 104.2 (14.7) 98.7 (17.7) 96.5 (13.7)
- FEV1 % pred 92.4 (19.9) 92.6 (21.4) 99.4 (11.3) 96.5 (8.4)
- FEV1 % VC ref 75.2 (10.4) 73.0 (12.8) 84.1 (9.8) 82.4 (8.9)
- PEF % pred 99.3 (23.8) 108.4 (42.9) 91.7 (14.9) 91.3 (16.0)
GINA classification 2.74 (0.7) 2.96 (0.5) 2.07 (0.7) 2.31 (0.8)
Gender
- male 33.3 % 42.3 % 55.6 % 72.4 %
- female 66.7 % 57.7 % 44.4 % 27.6 %
civil status
- single 22.2 % 7.7 % 0 % 0 %
- with parents 7.4 % 0 % 100 % 100 %
- married/living together 77.4 % 92.3 % 0 % 0 %
main daily activity
- paid employment 44.4 % 65.4 % 0 % 0 %
- sick leave/disabled 25.9 % 11.5 % 0 % 0 %
- school/college 3.7 % 0.0 % 100 % 100 %
- housekeeping 11.1 % 7.7 % 0 % 0 %
- other 14.8 % 15.4 % 0 % 0 %
FVC % pred = forced vital capacity expressed as a percentage of predicted; FEV1 % pred = forced expiratory volume in 1 second expressed as a 
percentage of predicted; FEV1 % VC ref = forced expiratory volume expressed as a percentage of predicted/vital capacity; PEF % pred = peak 
expiratory flow expressed as a percentage of predicted. GINA classification based on prescribed medication; 1 = intermittent asthma, 2 = 
persistently mild asthma, 3 = persistently moderate asthma, 4 = persistently severe asthma.Cost Effectiveness and Resource Allocation 2007, 5:10 http://www.resource-allocation.com/content/5/1/10
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version themselves, for children younger than 12 years of
age the parents or caregivers completed the child proxy
version.
The SF-6D is derived from the SF-36 [16]. The SF-6D
instrument covers 6 domains, and describes 18,000
health states. Using a fractional factorial design, 249
health states were identified and valued by a representa-
tive sample of the UK general population using the stand-
ard gamble valuation method [17]. An algorithm
provided by Brazier and colleagues was used to construct
the utilities. The utility scores range from 0.29 to 1.0. SF-
6D utilities could only be obtained in the subgroup of
adult participants because no child version is available.
Costs
Costs can be divided into health care costs, patient and
family costs, productivity losses, and costs in other sectors
[5]. Health care costs included costs associated with hos-
pital care, general practitioners and other health care pro-
fessionals, prescribed medication, professional home
care, and the intervention. Hospital care included day
admissions, emergency room visits, surgical and diagnos-
tic procedures, laboratory research, and outpatient visits.
Patient and family costs consisted of the costs of over-the-
counter medication, and informal care. Productivity
losses include the costs due to productivity loss at paid
and unpaid work. Costs in other sectors are the resources
consumed in other sectors, such as volunteer work and
nursing home care. These costs were absent in this study
and therefore not included in the analysis. The volumes of
hospital care were obtained from the hospital billing sys-
tem of the university hospital Maastricht. All other
resource use was collected using a four weeks prospective
cost diary completed at 1, 4, 8 and 12 months follow-up.
Cost diaries have proven to be a successful means to
gather information on healthcare resource use during a
longer period [18]. The data from each cost diary were
interpolated (multiplied by 3) in order to obtain esti-
mates of resource use during the entire one year follow-up
period.
Unit prices from the Dutch manual for cost research were
used if available [19]. Costs associated with the loss of
productivity at volunteer work or household activities
were calculated using a shadow price of € 8.30 per hour of
absence. Costs from productivity loss at paid work were
calculated according to the friction cost method [20]. This
method calculates productivity loss costs for the duration
of the friction period. The friction period is the theoretical
time needed to fill a vacancy as a result of illness. This
method is recommended by the Dutch guidelines for
pharmaco-economic research [21]. Costs of school absen-
teeism were incorporated in a sensitivity analysis. This cal-
Table 2: a. EQ-5D mean (SD) domain scores and utility score for Adults (18 years and older) in Control group (N = 27) and 
Intervention group (N = 26; total N = 53)
EuroQol Baseline Month 4 Month 8 Month 12
Control Intervention Control Intervention Control Intervention Control Intervention time1 time*group2
P
Mobility 1.37 (0.49) 1.15 (0.37) 1.32 (0.46) 1.00 (0.00) 1.35 (0.55) 1.15 (0.37) 1.30 (0.47) 1.54 (0.37) .000 .1903
Self care 1.07 (0.27) 1.00 (0.00) 1.04 (0.19) 1.04 (0.20) 1.11 (0.32) 1.04 (0.20) 1.22 (0.42) 1.04 (0.20) .000 .2134
Daily activities 1.48 (0.51) 1.35 (0.49) 1.54 (0.50) 1.31 (0.47) 1.54 (0.57) 1.42 (0.58) 1.56 (0.58) 1.46 (0.51) .004 .6233
Pain/discomfort 1.67 (0.56) 1.31 (0.47) 1.54 (0.57) 1.23 (0.43) 1.56 (0.58) 1.35 (0.49) 1.63 (0.63) 1.42 (0.50) .000 .8714
Anxiety/depression 1.11 (0.32) 1.19 (0.40) 1.22 (0.42) 1.15 (0.37) 1.19 (0.40) 1.27 (0.45) 1.19 (0.40) 1.15 (0.37) .001 .5054
VAS 67.33 (17.20) 74.57 (12.78) 71.67 (17.63) 73.08 (14.29) 68.11 (19.06) 71.35 (18.45) 72.26 (18.43) 74.50 (15.87) .081 .6384
Utility 0.78 (0.17) 0.89 (0.13) 0.80 (0.18) 0.91 (0.12) 0.78 (0.24) 0.86 (0.19) 0.79 (0.21) 0.90 (0.11) .010 .5963
b. EQ-5D mean (SD) domain scores and utility score for Children (7 to 18 years) in Control group (N = 27) and Intervention group (N = 29); total N = 56
EuroQol Baseline Month 4 Month 8 Month 12
Control Intervention Control Intervention Control Intervention Control Intervention time1 time*group2
P
Mobility 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.04 (0.19) - .4284
Self care 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) - -
Daily activities 1.15 (0.36) 1.21 (0.49) 1.07 (0.27) 1.09 (0.30) 1.04 (0.19) 1.14 (0.35) 1.11 (0.32) 1.14 (0.35) .000 .6214
Pain/discomfort 1.04 (0.19) 1.18 (0.47) 1.04 (0.19) 1.01 (0.03) 1.04 (0.19) 1.04 (0.19) 1.07 (0.27) 1.07 (0.26) .000 .8073
Anxiety/depression 1.11 (0.32) 1.10 (0.31) 1.04 (0.19) 1.00 (0.00) 1.07 (0.27) 1.04 (0.19) 1.15 (0.36) 1.00 (0.00) .000 .0643
VAS 81.36 (11.70) 79.61 (13.67) 84.32 (10.72) 81.29 (12.02) 83.32 (13.11) 82.59 (11.39) 81.33 (14.69) 82.31 (12.49) .000 .5214
Utility 0.96 (0.07) 0.92 (0.20) 0.98 (0.07) 0.99 (0.03) 0.98 (0.06) 0.98 (0.07) 0.97 (0.05) 0.98 (0.04) .000 .5573
P-values based on Repeated Measures ANCOVA corrected for baseline; performed separately for age group (adults/children).
1 p-value for overall follow-up in time.
2 p-value for follow-up difference in time between groups.
3 Greenhouse-Geisser.
4 Sphericity Assumed.
- = analyses could not be performed due to minimal to zero varianceCost Effectiveness and Resource Allocation 2007, 5:10 http://www.resource-allocation.com/content/5/1/10
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culation was mainly based on data of the Ministry of
Education, Culture and Science [22]. The hours of school
absenteeism were derived from the cost diaries. The costs
associated with school absenteeism consisted of govern-
ment costs and (voluntary) parental contribution and
these costs depend on school type and class. The total
costs were calculated by multiplying the hours of school
absenteeism with the corresponding unit prices.
For the costs of the intervention a micro costing calcula-
tion was performed. The intervention costs consisted of
costs of materials (the asthma monitor, and computer
equipment), costs of personnel (the nurse practitioner),
telephone costs, and travel costs. The price of the asthma
monitor was € 476, and the price of the modem € 1428.
Depreciation over five years, with 4,5 % interest, leads to
annual costs of € 434 per patient. The annual costs of an
insurance for the equipment amounted to € 16 per
patient. The costs of the computer equipment the nurse
practitioner used to receive and analyse the transferred
data (a personal computer, software, monitor, and
printer) amounted to € 1,150. For 55 patients, depreci-
ated over five years, with 4,5 % interest, these costs equal
€ 5 per patient per year. Other fixed costs were associated
with the development and production of instruction
material (€ 4 and € 7 per patient per year), and adminis-
trative tasks of the nurse practitioner (€ 7 per patient per
year). A continuous time registration of the activities
(reviewing the lung function data the patients send in,
adjusting the treatment plans, telephone contacts and
house calls) of the nurse practitioner was performed.
Based on the salary costs of a nurse practitioner (€ 44,700
per year), and 1540 workable hours per year, the costs of
the nurse practitioner were estimated to amount to € 29
per hour. Costs of repair of the asthma monitor and
modem were registered by the nurse practitioner.
Overhead costs were calculated over all direct material
and personnel costs (35%) [19]. All costs were calculated
for a period of one year, therefore discounting was not
indicated. Costs are presented in euro for the year 2002.
Statistical analyses
Analyses were performed by the intention-to-treat princi-
ple. Data imputations for missing values were carried out
consecutively in three steps. Firstly, overall mean scores at
baseline substituted missing baseline scores. Secondly,
missing scores between two valid scores measured in time
were individually interpolated. Thirdly, remaining miss-
ing values were imputed by Last Value Carried Forward
procedure. If data was normally distributed analysis on
the resulting complete data was done by repeated meas-
ures ANCOVA using 'time' as a fourth category within-
patients factor and both the experimental factor (control/
Table 3: SF36 mean (SD) domain scores and SF-6D mean (SD) utility score for adult (18 years and older) study participants in the 
Control group (N = 27) and Intervention group (N = 26)
SF36 Baseline Month 4 Month 8 Month 12 time1 time* group2
CI C I C I CI P
Physical functioning 68.06 72.42 67.05 75.62 66.02 71.20 68.79 71.58 .088 .4124
(24.3) (20.9) (25.7) (21.5) (26.9) (23.9) (25.7) (22.6)
Social functioning 66.20 75.96 71.99 76.92 71.99 74.52 72.22 78.37 .000 .7434
(26.4) (26.4) (26.3) (20.52) (27.0) (25.4) (25.6) (22.0)
Role physical 42.59 49.85 48.61 56.73 54.17 47.12 57.41 53.53 .001 .3274
(46.4) (44.2) (43.9) (43.9) (47.2) (45.5) (45.9) (45.5)
Role emotional 65.50 71.80 65.43 71.80 76.54 67.95 77.78 78.21 .000 .4384
(41.8) (41.8) (45.0) (41.8) (41.2) (46.7) (40.3) (38.8)
Mental health 71.74 75.29 74.30 71.39 71.56 73.69 76.59 77.23 .004 .3353
(17.4) (18.7) (17.7) (21.5) (18.9) (22.2) (17.6) (18.4)
Vitality 52.96 58.68 53.92 59.23 53.61 55.77 59.44 60.77 .074 .5743
(19.6) (20.9) (17.7) (22.4) (21.3) (21.7) (22.9) (23.6)
Bodily Pain 64.96 75.15 66.37 84.35 65.26 72.00 67.59 74.92 .000 .0644
(25.6) (24.4) (25.2) (18.9) (24.21) (24.9) (23.3) (21.7)
General Health 48.55 47.31 48.83 51.72 48.65 50.89 52.05 50.05 .011 .4593
(21.8) (22.0) (22.40) (21.7) (23.9) (24.2) (24.2) (21.3)
SF-6D utility 0.69 0.75 0.72 0.75 0.71 0.74 0.74 0.75 .012 .3013
(0.14) (0.13) (0.14) (0.13) (0.16) (0.15) (0.14) (0.14)
C = control group; I = intervention group.
Domain scores range 0–100.
P-values based on Repeated Measures ANCOVA corrected for baseline.
1 p-value for overall follow-up in time.
2 p-value for follow-up difference in time between groups.
3 Greenhouse-Geisser.
4 Sphericity Assumed.Cost Effectiveness and Resource Allocation 2007, 5:10 http://www.resource-allocation.com/content/5/1/10
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intervention) as well as type of patient (child/adult) as
dichotomous between factors. The full model ANCOVA
allowed for testing of first and second order interactions
between the covariate (baseline scale scores) and both fac-
tors.
Adjustments for baseline differences in health state utility
for follow-up took place. In the intervention group, for
children and adults apart, the utility scores during the fol-
low-up measurements were corrected with the mean dif-
ference in baseline utility between the intervention group
and the control group. All significant test results involved
2-tailed probabilities with alpha set at 0.05. Analyses were
performed according to the intention-to-treat principle.
Statistical analysis was performed using SPSS, version
12.0.
Cost-effectiveness analysis
The time horizon of the cost-effectiveness analyses was 1
year. The cost-effectiveness analysis was conducted from
both the health care and the societal perspective. Adults
and children were analysed separately. In the analyses
from both perspectives the mean incremental health care
costs were weighted against the mean incremental effect
in terms of quality adjusted life years (QALY). Since no
mortality occurred the QALY was calculated for each
patient by multiplying each of the four measured utility
values with 4 months. This calculation was performed by
the use of the EQ-5D utility (adults and children) and the
SF-6D utility (adults only). To obtain the incremental
QALY multiple regression analysis was applied to control
for the differences in baseline utility. To get insight into
the uncertainty around the incremental cost-effectiveness
ratio (ICER) nonparametric bootstrap simulations were
conducted [23]. Bootstrapping was performed on both
the incremental regression based QALY (based on both
the EQ-5D utility and the SF-6D utility) versus both the
incremental health care costs and the incremental societal
costs. In the bootstrap simulation 5000 random samples
of cost-effect pairs, of equal size of the original sample,
were selected with replacement. The scatter plots represent
points of which each signifies the incremental cost-effec-
tiveness ratio of one iteration of the bootstrap simulation.
From a decision-makers point of view, the probability that
a new treatment is cost-effective varies depending on what
society is prepared to pay per gain in effectiveness, the so-
called ceiling ratio. In the Netherlands € 80,000/QALY
gained has been mentioned [24]. Another mentioned ceil-
ing ratio is € 40,000/QALY gained. This is shown in cost-
effectiveness acceptability curves.
Sensitivity analyses
One-way sensitivity analyses are performed to test for the
impact of two cost components on the study results. In the
first analysis the total asthma monitor costs including
monitor, modem, batteries, and insurance (€ 450) were
set to zero in the intervention group. In the second analy-
sis the costs resulting from school absenteeism by chil-
dren were included in the societal costs.
Results
Study population
From patient records of the departments of Respiratory
Medicine and Paediatrics of our hospital 274 potentially
eligible asthmatic outpatients were identified and
approached by letter. Eighteen patients were not eligible
because of the absence of a house phone connection
(7%), and 147 patients refused to participate in the study
(54%). The most frequently reasons of the 40 adults and
26 children who registered their reason for not participa-
tion were: 'having no time' (29% adults; 14% children),
'being uninterested' (9% adults; 11% children), 'not expe-
riencing asthma symptoms' (5% adults; 8% children),
and 'finding participation too confronting' (5% adults;
2% children). Finally 40% was included in the study.
Between January 2003 and January 2004, 109 patients (53
adults and 56 children) were enrolled in the study. The
characteristics of the intervention and control group
appeared to be similar at baseline, except for baseline util-
ity. The patient characteristics of the study population are
presented in table 1. Of the 109 participants, seven
patients (5 intervention group; 2 control group) were lost
to follow-up. In total five patients of the 55 patients in the
intervention group were lost to follow-up (two adults and
three children). In the control group two of the 54
patients were lost to follow-up (one adult and one child).
The reason to stop participation was for one patient in the
control group immigration, further all lost to follow-up
occurred because the patients refused further participa-
tion. Reasons for these refusals were not given. In the
intervention group four cases of loss to follow-up took
Cost-effectiveness plane from a societal perspective with  EQ-5D utility for adults Figure 1
Cost-effectiveness plane from a societal perspective with 
EQ-5D utility for adults.
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place immediately after the baseline measurement, and
one case occurred after the third measurement at eight
months.
In the control group one patient was lost to follow-up
after the baseline measurement and one patient after the
third measurement at eight months.
Effects
Generic quality of life as measured with the EQ-5D
descriptive part showed little to no problems at all meas-
urements. The scores on the VAS indicated a moderate to
good self perceived health status in both groups. The pop-
ulation utility scores were higher than the scores on the
VAS. No differences between groups in time in the VAS
Table 4: Mean (SD) total costs per patient over one year for total group, and for Adults (18 years and older) and Children (7 to 18 
years) separate
Cost component Unit costs in 2002 € Adults mean (SD) in 2002 € Children mean (SD) in 2002 
€
Intervention N =
26
Control N = 27 Intervention N
= 29
Control N =
27
General practitioner practice
general practitioner visit 20.20/visit1 41 (69) 42 (69) 13 (24) 27 (106)
general practitioner telephone visit 10.10/visit1 4 (10) 5 (16) 3 (12) 0 (1)
assistant visit 20.20/visit1 8 (20) 17 (62) 11 (29) 4 (12)
assistant telephone visit 10.10/visit1 6 (19) 11 (31) 8 (17) 7 (15)
nurse practitioner visit 20.20/visit1 0 (0) 14 (59) 2 (11) 0 (1)
Hospital care
day admission 229.00/admission1 0 8 (44) 2 (4) 27 (132)
emergency room visit 139.00/visit1 0 5 (27) 2 (4) 33 (161)
surgical procedures costs/procedure2 54 (274) 0 4 (7) 12 (46)
diagnostic procedures costs/procedure2 15 (55) 64 (208) 43 (72) 39 (71)
laboratory research costs/procedure2 79 (379) 8 (37) 44 (126) 15 (35)
lung specialist outpatient visit 100.00/visit1 26 (81) 25 (80) 0 0
paediatric lung specialist outpatient visit 100.00/visit1 0 0 57 (180) 128 (358)
asthma nurse practitioner outpatient visit 62.72/visit3 104 (287) 17 (51) 55 (131) 17 (72)
other medical specialists outpatient visit 100.00/visit1 62 (193) 139 (265) 69 (146) 6 (21)
Other healthcare professionals
speech therapist 25.00/visit1 08  ( 4 3 ) 00
homoeopath 52.50/visit4 18 (68) 0 (1) 33 (129) 1 (2)
company medical officer 51.61/visit5 7 (30) 6 (29) 0 0
Prescribed medication
medication drug costs6 670 (353) 655 (763) 236(241) 199 (247)
pharmacist fee 6.45/prescription1 60 (30) 59 (33) 37 (22) 40 (22)
Professional home care 26.70/hour1 548 (1327) 634(1170) 35 (117) 33 (108)
Intervention costs cost calculation7 530 (57) - 537 (54) -
Subtotal health care costs 2,228 (1,582) 1,720 (1,742) 1,193 (582) 588 (850)
Over the counter medication out-of-pocket costs7 7 (18) 5 (18) 4 (10) 0 (1)
Informal care 8.30/hour1 127 (323) 62 (214) 3 (12) 3 (11)
Subtotal patient and family costs 2,361 (1,673) 1,787 (1,794) 1,200 (591) 592 (855)
Loss of productivity at volunteer work 8.30/hour1 20 (61) 12 (57) 1 (3) 1 (3)
Loss of productivity at household work 8.30/hour1 105 (264) 50 (150) 5 (17) 5 (15)
Loss of productivity at paid labour friction costs3,7 487 (1394) 99 (281) 0 0
Subtotal productivity losses 612 (1,390) 161 (352) 6 (20) 6 (18)
Total costs 2,973 (2,650) 1,948 (1,777) 1,206 (601) 597 (863)
Notes: 1 Oostenbrink, 2004. 2 Hospital billing system. 3 calculated from Oostenbrink et al. 4 Dutch Association of Classic Homoeopaths, NVKH. 5 
Occupational health Service. 6 Dutch Health Insurance council; http://www.fk.cvz.nl. 7 cost diary.Cost Effectiveness and Resource Allocation 2007, 5:10 http://www.resource-allocation.com/content/5/1/10
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scores were observed in the adults (P = .638; ANCOVA) or
the children (P = .521; ANCOVA). See table 2 and 3.
Overall, the adults in the intervention group experienced
fewer problems with regard to the items of the EQ-5D
including the baseline measurement then the control
group. In time, the domain scores all significantly
improved in both groups. Between the groups in time no
statistically significant differences were observed. SF-6D
scores and utility were relatively high, and slightly higher
in the intervention group at all measurements. The results
of the SF-6D among the adult participants showed the
same pattern as the scores on the EQ-5D. Differences
between the groups in time were not statistically signifi-
cant. See table 4.
The children in the control group experienced more prob-
lems with regard to anxiety/depression on the EQ-5D at
month 12 compared to the intervention group. The mean
utility scores were slightly higher in the control group at
baseline and all equalised during follow-up measure-
ments. In both groups the domain scores statistically
improved in time, but no statistical significant improve-
ment between the groups were observed.
Costs
Table 5 presents the mean (SD) costs for adults (18 years
and older) and children (7 to 18 years) separate. The
mean one year intervention costs amounted to € 530 (SD
€ 57) per adult and € 537 (SD € 54) per child. The largest
part of the intervention costs was associated with the fixed
costs (€ 473), and on average only a small proportion of
the intervention costs was variable (€ 37, SD € 12). Over-
all, the mean health care costs per patient were higher in
the intervention group (€ 2,228, SD € 1,582 adults; €
1,193, SD € 582 children) than in the control group (€
1,720, SD € 1,742 adults; € 588, SD € 850; children). The
cost difference between the groups was mainly caused by
the intervention costs. Apart of the intervention costs,
other costs were also slightly higher in the intervention
group. Besides the intervention costs, in both groups med-
ication costs and costs of professional home care
accounted for a large proportion of the health care costs.
Cost-effectiveness acceptability curves (base case and minus the asthma monitor costs) from a societal perspective with EQ- 5D utility for adults Figure 2
Cost-effectiveness acceptability curves (base case and minus the asthma monitor costs) from a societal perspective with EQ-
5D utility for adults.
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With regard to the adults the costs of informal care were
on average twice as high in the intervention group (€ 127,
SD € 323), as in the control group (€ 62, SD € 214). As a
result the difference in patient and family costs between
the groups is somewhat larger than the difference in
health care costs. The costs due to loss of productivity at
paid labour are on average five times higher among the
patients in the intervention group (€ 487, SD € 1,394),
than among the patients in the control group (€ 99, SD €
281). As a result, the total costs for adults and children are
higher in the intervention group (€ 2,973, SD € 2,650
adults; € 1,206, SD € 601 children), than in the control
group (€ 1,948, SD € 1,777 adults; € 597, SD € 863 chil-
dren).
Incremental Cost-effectiveness
The results of the incremental analysis are listed in table 5.
Among the adults the health care costs were on average €
508 higher in the intervention group. Based on the boot-
strap simulation, the 95% confidence interval (CI) of the
difference in health care costs ranged from -€ 114 to €
1,118. The difference in societal costs was larger (€ 1,026;
2.5th percentile € 231; 97th percentile € 1,889), due to the
higher productivity losses in the intervention group.
Based on EQ-5D utility, after adjustment for baseline dif-
ferences by multiple regression, on average 0.03 QALY
(2.5th percentile 0.00; 97th percentile 0.07 bootstrap anal-
ysis) was gained from the intervention. The mean incre-
mental cost-effectiveness ratio was € 15,366/QALY gained
from the health care perspective and € 31,035/QALY
gained from the societal perspective. The cost-effective-
ness acceptability curve shows that the probability of cost-
effectiveness was 85% at a ceiling ratio of € 80,000/QALY
gained and 59% at a ceiling ratio of € 40,000/QALY
gained from the societal perspective. Based on the SF-6D
utility the mean incremental cost-effectiveness ratio were
inferior from both the health care as the societal perspec-
tive.
Among the children health care costs were € 605 higher in
the intervention group (2.5th percentile € 319; 97th per-
centile € 862). The difference in societal costs was about
the same (€ 609; 2.5th percentile € 312; 97th percentile €
864). The utility adjusted for baseline differences by mul-
tiple regression on average 0.01 QALY (2.5th percentile
0.00; 97th percentile 0.02) was gained from the interven-
tion. From the health care perspective the mean ICER was
€ 58,726/QALY and from the societal perspective €
59,071/QALY gained. The cost-effectiveness acceptability
curve show that the probability of acceptance is 68% at a
ceiling ratio of € 80,000/QALY gained and 22% at a ceil-
ing ratio of € 40,000/QALY gained from the societal per-
spective.
Sensitivity analysis
Table 5 presents a sensitivity analysis in which the moni-
tor costs were set to zero and a sensitivity analysis in
which the costs resulting from school absenteeism were
included.
After leaving out the monitor costs, among the adults the
incremental health care costs changed from € 508 to € 58.
The incremental societal costs decreased from € 1,026 to
€ 576. From the health care prospective the mean incre-
mental cost-effectiveness ratio changed from € 15,366/
QALY gained to € 1,759/QALY gained and from the soci-
etal perspective from € 31,035/QALY gained to € 17,427/
QALY gained. The probability of cost-effectiveness at a
ceiling ratio of € 80,000/QALY gained, changed from
85% to 90% from the societal perspective. The incremen-
tal cost-effectiveness ratios based on the SF-6D utility
remained inferior. Among the children the incremental
health care costs changed from € 605 to € 156 and the
societal costs from € 609 to € 159. From the societal per-
spective the cost-effectiveness ratio changed from €
59,071/QALY gained to € 15,438/QALY gained. The
probability that that the intervention was cost-effective
changed from 68% to 93% at a ceiling ratio of € 80,000/
QALY gained. The figures 1, 2, 3, 4, 5 and 6 present cost-
effectiveness curves and cost-effectiveness planes of the
base case and the sensitivity analyses, in which the moni-
tor costs were subtracted.
In the control group 7 children had on average 22 hours
of school absenteeism and in the intervention group 6
children had on average 5 hours of school absenteeism. As
a result the costs of school absenteeism were € 86 (SD €
272) in the control group and € 20 (SD € 85) in the inter-
vention group. Taking these costs into account the incre-
mental societal costs changed from € 609 to € 542 (2.5th
percentile € 196; 97th percentile € 849). The cost-effec-
Cost-effectiveness plane from a societal perspective with  EQ-5D utility for children Figure 3
Cost-effectiveness plane from a societal perspective with 
EQ-5D utility for children.
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tiveness ratio changed from € 59,071/QALY gained to €
52,618/QALY gained. At a ceiling ratio of € 80,000/QALY
gained, the probability of cost-effectiveness changed from
68% to 73% from the societal perspective.
Discussion
This study compared the cost-effectiveness of a nurse-led
telemonitoring programme in asthmatic outpatients to
regular care. Patients were asked to transfer their monitor
data at least twice daily and by judging the received data
and following a stepwise intervention protocol the nurse
practitioner was able to act as the main caregiver in the
intervention group. In both groups the EQ-5D and the SF-
6D were used to obtain estimates of health state utilities.
One year, health care costs, patient and family costs, pro-
ductivity losses were calculated. The mean incremental
costs were weighted against the mean incremental effects
in terms of QALY.
No significant differences were found between the groups
with regard to generic quality of life. Overall, the mean
health care costs per patient were higher in the interven-
tion group than in the control group. The intervention
costs mainly caused the cost difference between the
groups, but not totally. The intervention costs the society
€ 31,035/QALY gained among adults and among children
€ 59,071/QALY gained. From the societal perspective the
probability of cost-effectiveness is 85% at a ceiling ratio of
€ 80,000/QALY gained among the adults and 68% among
the children. When the QALY was based on the SF-6D util-
ity the mean incremental cost-effectiveness ratios were
inferior from both the health care as the societal perspec-
tive. In conclusion the intervention appears to be more
cost-effective among adults.
If the monitor costs are excluded the incremental costs
decrease strongly among both the adults and the children.
The decrease of monitor costs results in a far more cost-
effective intervention. Given the fast developments in
information communication technology, this decrease in
price is expected to take place in the future. If the costs
with regard to the children's absence from school are
included, the cost-effectiveness ratio only decreases about
€ 6,000, and the probability of cost-effectiveness is still
moderate. With regard to the higher costs due to produc-
tivity losses in the intervention group caution should be
taken, as in the intervention group a greater proportion of
patients were paid employers.
Considering the results of this study the intervention is
certainly not cost saving, and especially among children,
of limited cost-effectiveness. This result is in contrast with
the results of a recent review, in which was found that only
in three out of twenty-one economic evaluations self-
Cost-effectiveness acceptability curves (base case and minus the asthma monitor costs) from a societal perspective with EQ- 5D utility for children Figure 4
Cost-effectiveness acceptability curves (base case and minus the asthma monitor costs) from a societal perspective with EQ-
5D utility for children.
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Table 5: Incremental costs, effects, and cost-effectiveness analysis
Base case Adults Children
Incremental costs
Health care costs €508 €605
(2.5th–97.5th percentile) (-114 to 1,118) (319 to 862)
Societal costs €1,026 €609
(2.5th–97.5th percentile) (231 to 1,889) (312 to 864)
Incremental utility adjusted for baseline differences by multiple regression
EQ-5D QALY1 0.03 0.01
(2.5th–97.5th percentile) (0.00 to 0.07) (0.00 to 0.02)
SF-6D QALY1 -0.01
(2.5th–97.5th percentile) (-0.07 to 0.03) -
Incremental cost effectiveness ratio
Health care perspective EQ-5D €15,366/QALY gained €58,726/QALY gained
Distributions on CEA plane origin NE NW SW SE origin NE NW SW SE
0% 91% 3% 0% 5% 0% 98% 2% 0% 0%
Health care perspective SF-6D inferior -
Distributions on CEA plane origin NE NW SW SE
0% 17% 77% 5% 1%
Societal perspective EQ-5D €31,035/QALY gained €59,071/QALY gained
Distributions on CEA plane origin NE NW SW SE origin NE NW SW SE
0% 96% 4% 0% 1% 0% 98% 2% 0% 0%
Societal perspective SF-6D inferior -
Distributions on CEA plane origin NE NW SW SE
0% 17% 83% 0% 0%
Sensitivity analysis (minus asthma monitor costs)
Incremental costsCost Effectiveness and Resource Allocation 2007, 5:10 http://www.resource-allocation.com/content/5/1/10
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Health care costs €58 €156
(2.5th–97.5th percentile) (-544 to 671) (-137 to 411)
Societal costs €576 €159
(2.5th–97.5th percentile) (-257 to 1,423) (-142 to 417)
Incremental cost effectiveness ratio
Health care perspective EQ-5D €1,759/QALY gained €15,092/QALY gained
Distributions on CEA plane origin NE NW SW SE origin NE NW SW SE
0% 91% 3% 0% 5% 0% 84% 1% 0% 15%
Health care perspective SF-6D inferior -
Distributions on CEA plane origin NE NW SW SE
0% 9% 46% 38% 7%
Societal perspective EQ-5D €17,427/QALY gained €15,438/QALY gained
Distributions on CEA plane origin NE NW SW SE origin NE NW SW SE
0% 89% 3% 0% 8% 0% 85% 2% 0% 13%
Societal perspective SF-6D inferior -
Distributions on CEA plane origin NE NW SW SE
0% 14% 76% 8% 2%
Sensitivity analysis (school costs included in analysis)
Incremental costs
Societal costs €542
(2.5th–97.5th percentile) (196 to 849)
Incremental cost effectiveness ratio
Societal perspective EQ-5D €52,618/QALY gained
Distributions on CEA plane origin NE NW SW SE
0% 97% 3% 0% 0%
Costs year 2002 in euro.
ICER = Incremental Cost-effectiveness Ratio.
Percentiles based on bootstrap procedure with 5000 replicates.
1 Utility scores at follow-up measurements are adjusted for between group baseline difference using the multiple regression method.
Table 5: Incremental costs, effects, and cost-effectiveness analysis (Continued)Cost Effectiveness and Resource Allocation 2007, 5:10 http://www.resource-allocation.com/content/5/1/10
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management programmes based on peak flow monitor-
ing, the total costs were higher in the intervention group
[25].
As described in a review of Gibson et al. (2003), education
in asthma-management which involves self-monitoring,
regular medical review, and a written action plan appear
to improve health outcomes the most. In this study no
written action plans were used, which may have reduced
the effectiveness. Therefore, it might be recommended to
entail this aspect in future asthma self-management pro-
grammes. Furthermore, it is necessary to be cautious in
generalizing these findings, as this is an one centre study
in a Dutch outpatient setting. Also, these results should
not be generalized to asthmatics with more severe symp-
toms or the results of economic evaluations with a longer
time horizon than one year. Another study limitation is
the use of interpolated diary data, which can lead to an
underestimation or overestimation of the actual resource
use during the follow-up year. However, administrating
diaries daily during one year is very aggravating and may
negatively influence recruitment and drop out. In general,
diaries are an accepted way to measure resource use and
productivity losses [5,18]. Moreover, any bias is likely to
have occurred in both groups. Furthermore, the question-
naire and diary compliance were very high. For these rea-
sons a simple strategy to impute missing data seems
justified.
In general the study population had mild to moderate
asthma and the patients did not report many asthma
symptoms. This is in accordance with the observed high
scores in the self-reported quality of life. Nevertheless
these patients were diagnosed with asthma and received
regular outpatient care for that reason. Home monitoring
has been suggested to be the most efficient for asthmatics
who are poor perceivers of asthma severity (Fishwick
1996). On the other hand, asthma patients with moderate
till severe asthma may have more benefit of the interven-
tion, since there is more room for improvement. This is
confirmed in the review of Liljas et al. (1994), in which
was stated that asthma self-management seems to be even
more cost-effective in patients with severe asthma. The
low variation in the generic quality of life scores may also
imply that the questionnaires were not sensitive enough
for this particular group, especially among children.
Though the patients only reported mild asthma symp-
toms, the health care costs in the study population were
relatively high, mainly caused by the intervention and
medication costs. This stresses the importance of health
services research in asthma self-management pro-
grammes, in order to maximise the effects and minimise
the costs of medical therapy.
Another reason why the intervention was of limited cost-
effectiveness could be that the intervention was initiated
separately instead of integrated into the total process of
care. That way the intervention may only partially contrib-
ute to the improvement of the total care process, both in
terms of health outcomes and costs. This underlines the
importance of integrated care in telemonitoring pro-
grammes.
Conclusion
In conclusion, if the outcome is measured by generic qual-
ity of life the nurse-led telemonitoring programme is of
limited cost-effectiveness in the study population. From
the societal perspective the probability of the programme
being cost-effective compared to regular care was 85% at
a ceiling ratio of € 80,000/QALY gained among the adults
and 68% among the children. However, a decrease in the
price of the asthma monitor will substantially increase the
probability of the programme to be cost-effective.
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Cost-effectiveness plane from a societal perspective with SF- 6D utility for adults Figure 5
Cost-effectiveness plane from a societal perspective with SF-
6D utility for adults.
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